BMRN Q2 2020 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$429M+10.8% YoY

Gross Profit

$332M77.2% margin

Operating Income

-$41M-9.5% margin

Net Income

-$29M-6.8% margin

EPS (Diluted)

$-0.16

QoQ Revenue Growth

-14.5%

Cash Flow

Operating Cash Flow

$28M

Free Cash Flow

-$6M

Stock-Based Comp.

$45M

Balance Sheet

Total Assets

$5.3B

Total Liabilities

$2.1B

Stockholders' Equity

$3.2B

Cash & Equivalents

$819M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$429M	$388M	+10.8%
Gross Profit	$332M	$310M	+6.8%
Operating Income	-$41M	-$41M	+1.0%
Net Income	-$29M	-$37M	+22.0%

Revenue Segments

Royalty And Other

$10M100%

Geographic Segments

UNITED STATES

$233M54%

Europe

$109M25%

Rest Of World

$50M12%

Latin America

$38M9%